Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Physiol Res ; 70(4): 579-590, 2021 08 31.
Artículo en Inglés | MEDLINE | ID: mdl-34062082

RESUMEN

Prolactin-releasing peptide (PrRP) has been proposed to mediate the central satiating effects of cholecystokinin (CCK) through the vagal CCK1 receptor. PrRP acts as an endogenous ligand of G protein-coupled receptor 10 (GPR10), which is expressed at the highest levels in brain areas related to food intake regulation, e.g., the paraventricular hypothalamic nucleus (PVN) and nucleus of the solitary tract (NTS). The NTS and PVN are also significantly activated after peripheral CCK administration. The aim of this study was to determine whether the endogenous PrRP neuronal system in the brain is involved in the central anorexigenic effect of the peripherally administered CCK agonist JMV236 or the CCK1 antagonist devazepide and whether the CCK system is involved in the central anorexigenic effect of the peripherally applied lipidized PrRP analog palm-PrRP31 in fasted lean mice. The effect of devazepide and JMV236 on the anorexigenic effects of palm-PrRP31 as well as devazepide combined with JMV236 and palm-PrRP31 on food intake and Fos cell activation in the PVN and caudal NTS was examined. Our results suggest that the anorexigenic effect of JMV236 is accompanied by activation of PrRP neurons of the NTS in a CCK1 receptor-dependent manner. Moreover, while the anorexigenic effect of palm-PrRP31 was not affected by JMV236, it was partially attenuated by devazepide in fasted mice. The present findings indicate that the exogenously influenced CCK system may be involved in the central anorexigenic effect of peripherally applied palm-PrRP31, which possibly indicates some interaction between the CCK and PrRP neuronal systems.


Asunto(s)
Depresores del Apetito/administración & dosificación , Colecistoquinina/metabolismo , Ingestión de Alimentos/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Hormona Liberadora de Prolactina/análogos & derivados , Núcleo Solitario/efectos de los fármacos , Animales , Quimiocinas CC/efectos de los fármacos , Quimiocinas CC/metabolismo , Devazepida/administración & dosificación , Ayuno , Antagonistas de Hormonas/administración & dosificación , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Masculino , Ratones Endogámicos C57BL , Núcleo Hipotalámico Paraventricular/metabolismo , Fragmentos de Péptidos/administración & dosificación , Hormona Liberadora de Prolactina/administración & dosificación , Proteínas Proto-Oncogénicas c-fos/metabolismo , Transducción de Señal , Sincalida/administración & dosificación , Sincalida/análogos & derivados , Núcleo Solitario/metabolismo
2.
Endocr Regul ; 51(2): 73-83, 2017 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-28609288

RESUMEN

OBJECTIVE: Fos protein expression in catecholamine-synthesizing neurons of the substantia nigra (SN) pars compacta (SNC, A8), pars reticulata (SNR, A9), and pars lateralis (SNL), the ventral tegmental area (VTA, A10), the locus coeruleus (LC, A6) and subcoeruleus (sLC), the ventrolateral pons (PON-A5), the nucleus of the solitary tract (NTS-A2), the area postrema (AP), and the ventrolateral medulla (VLM-A1) was quantitatively evaluated aft er a single administration of asenapine (ASE) (designated for schizophrenia treatment) in male Wistar rats preconditioned with a chronic unpredictable variable mild stress (CMS) for 21 days. Th e aim of the present study was to reveal whether a single ASE treatment may 1) activate Fos expression in the brain areas selected; 2) activate tyrosine hydroxylase (TH)-synthesizing cells displaying Fos presence; and 3) be modulated by CMS preconditioning. METHODS: Control (CON), ASE, CMS, and CMS+ASE groups were used. CMS included restraint, social isolation, crowding, swimming, and cold. Th e ASE and CMS+ASE groups received a single dose of ASE (0.3 mg/kg, s.c.) and CON and CMS saline (300 µl/rat, s.c.). The animals were sacrificed 90 min aft er the treatments. Fos protein and TH-labeled immunoreactive perikarya were analyzed on double labeled histological sections and enumerated on captured pictures using combined light and fluorescence microscope illumination. RESULTS: Saline or CMS alone did not promote Fos expression in any of the structures investigated. ASE alone or in combination with CMS elicited Fos expression in two parts of the SN (SNC, SNR) and the VTA. Aside from some cells in the central gray tegmental nuclei adjacent to LC, where a small number of Fos profiles occurred, none or negligible Fos occurrence was detected in the other structures investigated including the LC and sLC, PON-A5, NTS-A2, AP, and VLM-A1. CMS preconditioning did not infl uence the level of Fos induction in the SN and VTA elicited by ASE administration. Similarly, the ratio between the amount of free Fos and Fos colocalized with TH was not aff ected by stress preconditioning in the SNC, SNR, and the VTA. CONCLUSIONS: Th e present study provides an anatomical/functional knowledge about the nature of the acute ASE treatment on the catecholamine-synthesizing neurons activity in certain brain structures and their missing interplay with the CMS preconditioning.


Asunto(s)
Antipsicóticos/farmacología , Encéfalo/efectos de los fármacos , Condicionamiento Psicológico , Compuestos Heterocíclicos de 4 o más Anillos/farmacología , Neuronas/efectos de los fármacos , Proteínas Proto-Oncogénicas c-fos/efectos de los fármacos , Estrés Psicológico/metabolismo , Tirosina 3-Monooxigenasa/efectos de los fármacos , Animales , Área Postrema/citología , Área Postrema/efectos de los fármacos , Área Postrema/metabolismo , Encéfalo/citología , Encéfalo/metabolismo , Catecolaminas/biosíntesis , Dibenzocicloheptenos , Inmunohistoquímica , Locus Coeruleus/citología , Locus Coeruleus/efectos de los fármacos , Locus Coeruleus/metabolismo , Masculino , Bulbo Raquídeo/citología , Bulbo Raquídeo/efectos de los fármacos , Bulbo Raquídeo/metabolismo , Microscopía Fluorescente , Neuronas/metabolismo , Porción Compacta de la Sustancia Negra/citología , Porción Compacta de la Sustancia Negra/efectos de los fármacos , Porción Compacta de la Sustancia Negra/metabolismo , Porción Reticular de la Sustancia Negra/citología , Porción Reticular de la Sustancia Negra/efectos de los fármacos , Porción Reticular de la Sustancia Negra/metabolismo , Puente/citología , Puente/efectos de los fármacos , Puente/metabolismo , Proteínas Proto-Oncogénicas c-fos/metabolismo , Ratas , Ratas Wistar , Núcleo Solitario/citología , Núcleo Solitario/efectos de los fármacos , Núcleo Solitario/metabolismo , Estrés Psicológico/psicología , Tirosina 3-Monooxigenasa/metabolismo , Área Tegmental Ventral/citología , Área Tegmental Ventral/efectos de los fármacos , Área Tegmental Ventral/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...